AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

NCT04058145 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding Withdrawn

Conditions

Head and Neck Cancer

Interventions

DRUG: AMD3100
DRUG: Pembrolizumab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]